Clinical Trial Update: Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine [Phase 1]

View source ↗

Summary

Phase 1 study from the University of Oxford evaluates the safety and immunogenicity of the Bacille Calmette-Guérin (BCG) vaccine in tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)

Snippet

Sponsor: University of Oxford | Conditions: TB | Phase 1 | Status: COMPLETED